A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis

Prior treatment

• Major surgical procedure within 8 weeks before screening, or will not have fully recovered from surgical procedure, or has a surgical procedure planned during the time the participant is expected to participate in the study
• Transplanted organ (with exception of a corneal transplant greater than \[\>\] 12 weeks before the first administration of study intervention)

Other illness

• Known allergies, hypersensitivity, or intolerance to JNJ-77242113, ustekinumab, or its excipients

Lab values

• Current drug-induced psoriasis (e.g., a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)

Other

• Nonplaque form of psoriasis (for example \[e.g.\], erythrodermic, guttate, or pustular)

• Diagnosis of plaque psoriasis, with or without psoriatic arthritis (PsA), prior to the first administration of study intervention
• Total body surface area (BSA) greater than or equal to (\>=)10 percent (%) at screening and baseline
• Total psoriasis area and severity index (PASI) \>=12 at screening and baseline
• Total investigator global assessment (IGA) \>=3 at screening and baseline
• Candidate for phototherapy or systemic treatment for plaque psoriasis